Klaus Wagner
Chief Tech/Sci/R&D Officer at BOUNDLESS BIO, INC.
Net worth: - $ as of 31/05/2024
Klaus Wagner active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BOUNDLESS BIO, INC. | Chief Tech/Sci/R&D Officer | 20/02/2022 | - |
Career history of Klaus Wagner
Former positions of Klaus Wagner
| Companies | Position | Start | End |
|---|---|---|---|
| INHIBRX, INC. | Chief Tech/Sci/R&D Officer | 01/08/2015 | 01/02/2022 |
Training of Klaus Wagner
| Friedrich-Alexander University of Erlangen-Nuremberg | Doctorate Degree |
Statistics
International
| United States | 3 |
| Germany | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| BOUNDLESS BIO, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
- Stock Market
- Insiders
- Klaus Wagner
- Experience
